ClinicalTrials.gg
Drug

Nirmatrelvir clinical trials

Also written PF-07321332.

studies test it
28
open now
3
in phase 3
6
first study started
2016

Counted the way a researcher would: Nirmatrelvir with its salts, dosage forms, brands and biosimilars. Looking for a trial to join? Including related medicines shows more you could take part in.

This browser remembers your choice.

How each study uses nirmatrelvir is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the nirmatrelvir studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
25 May 2023 · PAXLOVID (COPACKAGED) · NDA 217188 (FDA, Drugs@FDA; in a combination)
European Union
28 Jan 2022 · Paxlovid · EMEA/H/C/005973 (EMA; in a combination)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Nirmatrelvir
9
Paxlovid
2

Development codes

PF-07321332
6

In one entry with another drug

Given together, or one or the other

PF-07321332/ritonavir
7

Studies by the year they started

28 studies that test it; most in 2022 (13)

Studies that test nirmatrelvir, by start year
YearStudies
20161
20201
202112
202213
20231

By phase

A phase 1/2 study counts in both.

Phase 1
16
Phase 2
9
Phase 3
6

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 23 · Other 5

Pfizer (22) · University of Melbourne (1) · Stanford University (1) · Harlan M Krumholz (1) · Genuine Research Center, Egypt (1) · UMC Utrecht (1) · University of Oxford (1)

Often tested with

Tested in the same studies.

Ritonavir (11) · Remdesivir (3) · Hydroxychloroquine (2) · Ivermectin (2) · Nirmatrelvir and ritonavir drug combination (2) · Nafamostat (1) · Enoxaparin (1) · Dalteparin (1)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 1

Studies that test nirmatrelvir.

Studies

Open first, then newest update. How each study uses nirmatrelvir is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 28

See all 28 studies that test nirmatrelvir →

As the comparator · 1 — what is tested is compared with nirmatrelvir

Codes

What other systems call nirmatrelvir · ClinicalTrials.gg INT001662

  • MeSH (NLM) C000718217nirmatrelvirConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) 7R9A5P7H32NIRMATRELVIRConfirmed FDA, NLM, Wikidata
  • RxNorm 2587892One source FDA
  • Wikidata Q106405348nirmatrelvirConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C182119NirmatrelvirOne source FDA
  • DrugBank DB16691One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.